Abstract
Readouts from the thrombin generation (TG) assay (TGA) have been used to predict the effects of hemostatic drugs in hemophilic patients (1). There is better correlation between individual's bleeding tendency and their TG capacity compared to factor levels measured using routine assays (2-3). However, the clinical utility of TGA has not yet been validated in multicenter studies because of lack of standardization. This report aims to highlight variables that may impact directly on TGA reliability, and steps to reduce TGA variability within and between laboratories to improve precision of results. There are two semi-automated (CAT (Stago, Asnieres, France), Technothrombin-TGA (Technoclone, Viena, Austria) and two fully-automated (CEVERON® alpha w. TGA (Technoclone), ST-Genesia (Stago)) instruments that use fluorogenic thrombin substrates. Three instruments on the market use chromogenic thrombin substrates (HemoScan Thrombin Generation Assay (HemoScan, Groningen, The Netherlands), Pefakit in-TDT (Pentapharm, Aesch, Switzerland), Innovance ETP (Siemens Healthcare SAS, Erlangen, Deutschland). This article is protected by copyright. All rights reserved.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
